”With the submission of these two patent applications in the field of organ transplantation, we significantly strengthen our IP position,” said iCoat Medical’s CEO Peder Waern.

iCoat Medical continues to develop its technology platform and associated IP portfolio based on its coating technology. The company now has 40 patents and patent applications with international coverage within a total of five patent portfolios.

For more information, please contact:
Peder Waern, CEO – iCoat Medical AB
E-mail: peder.waern@icoatmedical.com
 
Mattias Springare, CFO and Head of Investor Relations – iCoat Medical AB
E-mail: mattias.springare@icoatmedical.com

About iCoat Medical
iCoat Medical is a clinical stage, pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform.

iCoat Medical’s lead candidate iCM012 is developed to improve the outcome of organ transplantations. The company’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund, and Malmö, and is headquartered in Stockholm.

For more information, please visit https://www.icoatmedical.com/sv/.